Filtered By:
Source: Stroke
Drug: Coumadin

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 77 results found since Jan 2013.

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation Clinical Sciences
Conclusions— In patients with nonvalvular atrial fibrillation and an increased risk of stroke prophylaxis, apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg were all cost-effective alternatives to warfarin. The cost-effectiveness of novel oral anticoagulantss was dependent on therapy pricing in the United States and neurological events associated with rivaroxaban 20 mg.
Source: Stroke - May 24, 2013 Category: Neurology Authors: Harrington, A. R., Armstrong, E. P., Nolan, P. E., Malone, D. C. Tags: Other anticoagulants, Embolic stroke, Anticoagulants Clinical Sciences Source Type: research

Amino Terminal Pro-B-Type Natriuretic Peptide, Secondary Stroke Prevention, and Choice of Antithrombotic Therapy Clinical Sciences
Conclusions— For secondary stroke prevention, elevated NT-proBNP concentrations may identify a subgroup of ischemic stroke patients without known atrial fibrillation, about 5% based on the current study, who may benefit more from anticoagulants than antiplatelet agents. Clinical Trial Registration— This trial was not registered because enrollment began before 2005.
Source: Stroke - February 25, 2013 Category: Neurology Authors: Longstreth, W. T., Kronmal, R. A., Thompson, J. L. P., Christenson, R. H., Levine, S. R., Gross, R., Brey, R. L., Buchsbaum, R., Elkind, M. S. V., Tirschwell, D. L., Seliger, S. L., Mohr, J. P., deFilippi, C. R. Tags: Primary and Secondary Stroke Prevention Clinical Sciences Source Type: research